MIV Therapeutics Named to Top 100 Nanotechnology Companies by International Association of Nanotechnology; Developer of Novel Biomedical Coatings in Same Top 100 List as Major Wall Street and Fortune 500 Companies
The IAnano ranking puts MIVT in the same Top 100 list as major Wall Street and Fortune 500 companies involved in nanotechnology development, including Boston Scientific, Eli Lilly, Dow Chemical, Hewlitt-Packard, IBM and 3M, among others. IAnano, a nonprofit organization that fosters research and progress in the science of nanotechnology, highlighted the medical promise of MIVT's proprietary nanotechnology-based coatings for medical implants, such as drug-eluting cardiovascular stents.
“List of 100 Leading Nanotechnology Public Companies.”
According to IAnano, the selection of the companies is based on the following five criteria: 1) A company's current involvement in R&D, manufacturing and marketing of nanotechnology products and services; 2) intellectual property position in nanotechnology; 3) advanced engineering processes in nanotechnology and nanoscale manufacturing and production; 4) impact in the marketplace; and 5) sales and revenue derived from nanotechnology products or services.
MIVT is a developer of unique, ultra-thin biocompatible and polymer-free coatings for vascular stents, internal drug delivery systems and other medical applications, whose research and development program is based heavily on the advanced development of nanotechnology. Its first product line will be launched in 2007, and will target the estimated $160 billion marketplace for localized drug delivery technologies.
The firm is committed to the development and commercialization of a variety of unique, biocompatible coating applications for wide-ranging therapeutic purposes, using its proprietary hydroxyapatite (HAp) platform technology. This HAp platform can enable the surface of stents and other major implanted devices to virtually mimic the natural state of structurally-sound, 100% biocompatible and bio-active tissue.
Hydroxyapatite (HAp), unlike polymer coatings, is derived naturally and found in such bioceramic materials as human bone and teeth.
The IAnano Leading 100 list can be viewed by visiting http://www.ianano.org/Fortune-Nanotech.pdf. MIVT was also a sponsor of the Fortune 500 special advertorial section on nanotechnology, which can be viewed online by visiting such websites as www.CNNMoney.com and http://www.ianano.org/Fortune-Nanotech.pdf.
The International Association of Nanotechnology is a non-profit organization with the goals to foster scientific research and business development in the areas of Nanoscience and Nanotechnology for the benefits of society. The Association believes that nanotechnology products (especially new nanomaterials) should be thoroughly studied, developed and produced with a well controlled manner to ensure safety to the workers and the consumers, within the internationally adopted standards. With proper safeguards, this emerging technology would have positive impact on the quality of our lives and the environment, not only in this generation but generations to come. For more information, please visit: http://www.ianano.org/.
About MIV Therapeutics Inc.
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.